Our Business
InteKrin’s mission, under the guidance of InteKrin’s experienced Management Team and world-class Scientific Advisory Board and Board of Directors is to develop our lead candidate INT-131 to meet unmet patient needs.
Read More
Recent News
June 29, 2010
InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
June 18, 2010
InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
Read More